Fairvalue-Calculator Fairvalue-Calculator
EN DE

Assembly Biosciences, Inc (ASMB) Fair Value & Analysis

Healthcare · US · Market cap $500M

Price$26.80
Fair Value$46.95
Upside+75.2%
Quality95/100
Evidence: Low Range $35.21 – $58.68

Fair value as of: Jun 24, 2026

Analysis

Assembly Biosciences, Inc (ASMB) currently trades at $26.80, while our model-based Fair Value estimate is $46.95 — implying the stock looks roughly 75.2% undervalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.

About the company

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection. The company also develops ABI-4334, an orally bioavailable next generation capsid assembly modulator that is in Phase 1b study clinical trial for the treatment of chronic hepatitis B virus (HBV) infection; and ABI-7272, an oral broad-spectrum NNPI for the treatment of transplant-associated herpesviruses. It has an option, license, and collaboration agreement with Gilead Sciences, Inc. for the research and development of virology therapies. The company was formerly known as Ventrus Biosciences, Inc. and chan…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -88% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -62%

Frequently asked questions

Is Assembly Biosciences, Inc (ASMB) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $46.95 versus a price of $26.80 — about +75% (undervalued). Model-based estimate, not financial advice.
What is the fair value of ASMB?
Our 21-model fair value for Assembly Biosciences, Inc is $46.95 (as of Jun 24, 2026), built from audited fundamentals. The current price is $26.80.
What is the quality score of ASMB?
Assembly Biosciences, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.